Royalty Pharma Sub-Manager, LLC

In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 21, 2026), Royalty Pharma Sub-Manager, LLC reported 4 stock positions worth $241.9 million. Its top holding was Cytokinetics (CYTK) at 34.5% of the portfolio, followed by Zenas Biopharma (ZBIO, 25.1%) and Kailera Therapeutics (KLRA, 22.4%). Compared with Q1 2026, it opened 1 new position and sold out of 1. The biggest buy was a new position in Kailera Therapeutics (KLRA) and the biggest sale an exit from Biocryst Pharmaceuticals (BCRX).